This is a non-core endpoint: only basic statistics are computed.
Glucagon-like peptide-1 (GLP-1) analogues
GLP1ANA
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
A10BH
1 out of 7 registries used, show all original rules.
19340
Check minimum number of events
Min. number of events
3
19340
Include endpoints None
19340
Remove individuals based on genotype QC
18678
GLP1ANA
Control definitions
Control exclude
DIAB_MED_OTHER
Extra metadata
First used in FinnGen datafreeze
DF2
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Glucagon-like peptide-1 (GLP-1) analogues
based on the number of shared cases.
Broader endpoints:
- Other (not insulin) diabetes medications
- Diabetes medication
- Type 2 diabetes
- Diabetes 1 & 2, IBD co-morbidity
- Diabetes mellitus
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 18678 | 8103 | 10575 |
| Unadjusted prevalence (%) | 4.95 | 3.84 | 6.36 |
| Mean age at first event (years) | 65.50 | 65.06 | 65.84 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Glucagon-like peptide-1 (GLP-1) analogues
↥Endpoint not on priority list, no data to show.